OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab Dec 14, 2017
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform Nov 28, 2017
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 Nov 9, 2017
OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients Nov 8, 2017
OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company Nov 7, 2017
OncoSec Closes $7.1 Million Registered Direct Offering Priced At-the-Market and Announces $1.1 Million Registered Direct Offering Priced Above Market Oct 25, 2017
